Article

25 Things About Me

Author(s):

Linnea Olson

I have stage 4 lung cancer. Here are 24 other things about me.

  1. I have stage 4 lung cancer; the histology is invasive mucinous adenocarcinoma.
  2. I was diagnosed when I was 45 years old.
  3. The youngest of my three children was seven.
  4. That was 10 years ago — it will be 11 years in April (woohoo!)
  5. My first line of treatment was a lower left lobectomy followed by four rounds of adjuvant chemotherapy.
  6. Staged at 1b initially, I was hoping I’d be cured.
  7. My cancer came back almost immediately.
  8. For two years, we watched and waited as there were no other viable treatments.
  9. By June 2008, I had more than 33 tumors in my lungs and a biopsy confirmed metastatic spread.
  10. I was told I had three to five months to live.
  11. This was one week before my daughter got married.
  12. Even though EGFR-negative, I started Tarceva (erlotinib) as a last ditch effort and began to say goodbye to family.
  13. At a scan review in September, it was clear that my cancer was spreading but there was good news.
  14. My biopsy showed that I was ALK-positive and a phase 1 trial targeting ALK mutations had just opened.
  15. On October 1, 2008, I became the fourth person in the world with NSCLC to take Xalkori (crizotinib).
  16. I felt better within days of regular dosing.
  17. My scan review six weeks later showed almost complete resolution of the cancer in my lungs.
  18. I took Xalkori for three years before progression forced me to switch therapies.
  19. I enrolled on another phase 1 clinical trial for Zykadia (ceritinib/LDK378) with similar results.
  20. This time, I got 18 months out of an experimental therapy.
  21. When I came off trial, I returned to chemotherapy again for six months and then I took a break.
  22. I went almost a year without treatment (glorious!) but I was also becoming more symptomatic.
  23. In May 2014, I enrolled into my third phase 1 clinical trial for PF-006463922/lorlatinib — once again I responded.
  24. My cancer has been stable for 18 months and I feel fabulous.
  25. I can’t wait to share more of my story with the readers of CURE!

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content
Image of breast.
April 30th 2025

FDA Completes Review of Hepzato Combo in HER2– Metastatic Breast Cancer

Ryan Scott
The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Illustration of woman with blonde hair.
April 30th 2025

Lingering Stress After Follicular Lymphoma Remission is a Challenge

Karen Cohn
Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue to weigh heavily on me.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Illustration of brain.
April 30th 2025

Larger Tumor Size Linked to Higher Mortality Risk in Brain Cancer

Ryan Scott
Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.
An illustration of blood cancer
April 30th 2025

SENTI-202 Shows Positive Preliminary Data in Acute Myeloid Leukemia

Spencer Feldman
A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia.